The IUS that can be used in many women1

According to the CDC recommendations, Paragard may
be used with no restrictions in over 20 medical conditions including but not limited to1:

  • Breast cancer (family history, current, past, and no evidence of current disease for 5 years)
  • Cystic fibrosis
  • Depression
  • Diabetes
  • Epilepsy
  • Gallbladder disease
  • Headaches, including migraines with and without auras and menstrual migraines
  • History of bariatric surgery
  • History of high blood pressure during pregnancy
  • History of stroke
  • Hypertension
  • Inflammatory bowel disease including ulcerative colitis and Crohn’s disease
  • Ischemic heart disease
  • Liver tumors
  • Lupus
  • Malaria
  • Multiple sclerosis (MS)
  • Ovarian cancer
  • Ovarian cysts
  • Past ectopic pregnancy
  • Risk factors for cardiovascular disease, including smoking
  • Thyroid disease
  • Viral hepatitis
  • Valvular heart disease
  • Women with a body mass index (BMI) greater than or equal to 30

Before prescribing the Paragard IUS, make sure that the patient is an appropriate candidate and exclude pregnancy prior to use. See full list of Contraindications, and Warnings and Precautions in the Paragard Full Prescribing Information.

According to CDC, Paragard should not be used for patients with distorted uterine cavity, cervical cancer awaiting treatment, endometrial cancer, persistently elevated B-hCG levels or malignant disease, with evidence or suspicion of intrauterine disease associated with Gestational trophoblastic disease.

Make Paragard IUS the first choice for women who…

  • Aren’t satisfied with their current birth control
  • Try to lead a hormone-free lifestyle and avoid artificial hormones in their food and prefer to avoid them in their birth control as well
  • Prefer to keep their menstrual cycle
  • Are busy and prefer a low maintenance birth control with no daily routine—just a simple monthly thread check
  • Are done having kids and looking for a long-term birth control option
  • Want a birth control that’s immediately reversible if she decides she wants to get pregnant

Access our new Online Virtual Training Simulation

click here

Important Safety Information

CONTRAINDICATIONS

  • The use of Paragard is contraindicated when one or more of the following conditions exist:
    • Pregnancy or suspicion of pregnancy, abnormalities of the uterus resulting in distortion of the uterine cavity, acute pelvic inflammatory disease (PID), postpartum or postabortal endometritis in the past 3 months, known or suspected uterine or cervical malignancy, uterine bleeding of unknown etiology, untreated acute cervicitis or vaginitis or other lower genital tract infection, conditions associated with increased susceptibility to pelvic infections, Wilson’s disease, a previously placed IUS that has not been removed, hypersensitivity to any component of Paragard including to copper or any of the trace elements present in the copper component of Paragard. Continue reading

INDICATIONS AND USAGE

Paragard is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 10 years.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • The use of Paragard is contraindicated when one or more of the following conditions exist:
    • Pregnancy or suspicion of pregnancy, abnormalities of the uterus resulting in distortion of the uterine cavity, acute pelvic inflammatory disease (PID), postpartum or postabortal endometritis in the past 3 months, known or suspected uterine or cervical malignancy, uterine bleeding of unknown etiology, untreated acute cervicitis or vaginitis or other lower genital tract infection, conditions associated with increased susceptibility to pelvic infections, Wilson’s disease, a previously placed IUS that has not been removed, hypersensitivity to any component of Paragard including to copper or any of the trace elements present in the copper component of Paragard.

WARNINGS AND PRECAUTIONS

  • Ectopic Pregnancy: Evaluate for possible ectopic pregnancy in any female who becomes pregnant while using Paragard.
  • Intrauterine Pregnancy: Failure to remove Paragard increases the risk of miscarriage, sepsis, premature labor, and premature delivery.
  • Sepsis: Severe infection or sepsis, including Group A Streptococcal Sepsis (GAS), have been reported following insertion of IUSs, including Paragard.
  • Pelvic Inflammatory Disease and Endometritis: Remove Paragard in cases of recurrent PID or endometritis, or if an acute pelvic infection is severe or does not respond to treatment.
  • Embedment: Partial penetration or embedment of Paragard in the myometrium can make removal difficult; surgical removal may be necessary. Breakage of an embedded Paragard during non-surgical removal has been reported.
  • Perforation: Partial or total perforation of the uterine wall or cervix may reduce contraceptive efficacy and result in pregnancy. Delayed detection or removal of Paragard may result in migration outside the uterine cavity, adhesions, peritonitis, intestinal penetration, intestinal obstruction, abscesses and/or damage to adjacent organs. Increased risk when the uterus is fixed, retroverted or not completely involuted during the postpartum period. If perforation does occur, locate and remove Paragard promptly.
  • Expulsion: Partial or complete expulsion of Paragard has been reported, resulting in the loss of contraceptive protection. The risk of expulsion may be increased when the uterus is not completely involuted at the time of insertion. Remove a partially expelled Paragard.
  • Wilson’s Disease: Paragard may exacerbate Wilson’s disease.
  • Bleeding Pattern Alterations: Paragard can alter the bleeding pattern and result in heavier and longer menstrual cycles with intermenstrual spotting.
  • Magnetic Resonance Imaging (MRI) Safety Information: Non-clinical testing has demonstrated that Paragard is MR Conditional.
  • Medical Diathermy: Avoid using high medical RF transmitter devices in females with Paragard.

ADVERSE REACTIONS

  • Adverse reactions reported in clinical trials include anemia, backache, dysmenorrhea, dyspareunia, expulsion (complete or partial), prolonged menstrual flow, menstrual spotting, pain and cramping, and vaginitis.

Please see full Prescribing Information

Reference:
 1. Centers for Disease Control and Prevention. National Center for Chronic Disease Prevention and Health Promotion. Summary Chart of U.S. Medical Eligibility Criteria for Contraceptive Use; 2020.